Axsome Therapeutics Axsome Therapeutics (AXSM) is a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) conditions. The Company  delivers  scientific breakthroughs by identifying critical gaps in care and develop differentiated products with a focus on novel mechanisms of action that enable meaningful advancements in patient outcomes. Axsome industry-leading neuroscience portfolio includes FDA-approved . . . This content is for …

Axsome Therapeutics Inc and Major Depressive Disorder In a teleconference on August 20, 2021, the U.S. Food and Drug Administration (FDA) informed Axsome Therapeutics (AXSM) that its review of the new drug application (NDA) for AXS-05, for the treatment of major depressive disorder, would not be completed by the Prescription Drug User Fee Act (PDUFA